PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
CRH plc (CRH)
114.271.68 (1.49%)
111.48 - 114.40
76.75 - 114.40
5.09M / 4.23M (Avg.)
23.96 | 4.77
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-23.83%
Both firms have declining sales. Martin Whitman would suspect an industry slump or new disruptive entrants.
-41.87%
Both firms have negative gross profit growth. Martin Whitman would question the sector’s viability or cyclical slump.
-97.12%
Negative EBIT growth while JHX is at 180.24%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-98.37%
Negative operating income growth while JHX is at 180.24%. Joel Greenblatt would press for urgent turnaround measures.
-112.82%
Negative net income growth while JHX stands at 179.32%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-114.56%
Negative EPS growth while JHX is at 176.92%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-114.71%
Negative diluted EPS growth while JHX is at 176.92%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
-0.25%
Both firms reduce share counts. Martin Whitman would compare buyback intensity relative to free cash flow generation.
-1.02%
Both reduce diluted shares. Martin Whitman would review each firm’s ability to continue repurchases and manage option issuance.
5.91%
Dividend growth of 5.91% while JHX is flat. Bruce Berkowitz would see if this can become a bigger advantage long term.
-124.14%
Negative OCF growth while JHX is at 8.52%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-172.97%
Negative FCF growth while JHX is at 12.51%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
15.40%
10Y revenue/share CAGR under 50% of JHX's 144.13%. Michael Burry would suspect a lasting competitive disadvantage.
15.40%
5Y revenue/share CAGR under 50% of JHX's 54.08%. Michael Burry would suspect a significant competitive gap or product weakness.
15.40%
3Y revenue/share CAGR at 50-75% of JHX's 20.55%. Martin Whitman would question if the firm lags behind competitor innovations.
-7.82%
Negative 10Y OCF/share CAGR while JHX stands at 331.81%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
-7.82%
Negative 5Y OCF/share CAGR while JHX is at 30.19%. Joel Greenblatt would question the firm’s operational model or cost structure.
-7.82%
Both face negative short-term OCF/share growth. Martin Whitman would suspect macro or cyclical issues hitting them both.
-268.56%
Negative 10Y net income/share CAGR while JHX is at 451.76%. Joel Greenblatt sees a major red flag in long-term profit erosion.
-268.56%
Negative 5Y net income/share CAGR while JHX is 83.35%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
-268.56%
Negative 3Y CAGR while JHX is 31.23%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
12.03%
Below 50% of JHX's 596.10%. Michael Burry would suspect poor capital allocation or persistent net losses eroding long-term equity build-up.
12.03%
Below 50% of JHX's 108.64%. Michael Burry sees a substantially weaker mid-term book value expansion strategy in place.
12.03%
Below 50% of JHX's 67.45%. Michael Burry suspects a serious short-term disadvantage in building book value.
-64.08%
Both reduced dividends long-term. Martin Whitman might check if sector-level headwinds forced universal cuts.
-64.08%
Negative 5Y dividend/share CAGR while JHX stands at 0.00%. Joel Greenblatt sees a weaker commitment to dividends vs. a competitor that might be growing them.
-64.08%
Both firms reduced dividends recently. Martin Whitman suspects broader macro or industry issues forcing cost and payout cuts.
6.66%
AR growth well above JHX's 0.43%. Michael Burry fears inflated revenue or higher default risk in the near future.
4.31%
Inventory shrinking or stable vs. JHX's 9.24%. David Dodd confirms the company’s supply-chain is more efficient if sales are unaffected.
2.58%
Asset growth above 1.5x JHX's 0.31%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
-1.91%
We have a declining book value while JHX shows 5.48%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
11.01%
We have some new debt while JHX reduces theirs. John Neff sees the competitor as more cautious unless our expansions pay off strongly.
No Data
No Data available this quarter, please select a different quarter.
-5.17%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.